Martin Shkreli is an American hedge fund manager and entrepreneur, specializing in healthcare businesses, and is a co-founder of MSMB Capital Management and the founder of Turing Pharmaceuticals AG. He is a co-founder and was the chief executive officer of Retrophin LLC, a biotechnology firm founded in 2011.
Senior columnist for The Street. Before joining The Street in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
David Kliff is the Publisher of Diabetic Investor, the only investment newsletter covering the diabetes care industry. An insulin-using Type II diabetic diagnosed in 1996, Mr. Kliff offers a unique perspective on the industry due to his firsthand knowledge of living with diabetes. He earned a B.A. in speech communications from the University of Illinois.
Jason Karp is chief investment officer and CEO of Tourbillon Capital Partners, L.P., a $2.3-billion global long/short equity fund that has low net exposure and aims to generate superior risk-adjusted returns while seeking limited correlation to the equity markets. Prior to launching Tourbillon, Karp was co-chief investment officer and a partner at Carlson Capital, where he co-managed the firm portfolios alongside founder Clint Carlson. At Carlson Capital, he was also responsible for portfolio and firm-level risk management, firm-wide allocation decisions, talent selection and the oversight and training of the equity investment staff. Previously, Karp was a portfolio manager at SAC Capital and a partner and portfolio manager at George Weiss Associates. He is a trustee and chair of the investment committee overseeing Loomis Chaffee’s endowment. Karp has a B.S. in economics from the Wharton School of the University of Pennsylvania.
Not on the list?
We forgot a bear on that list? Drop us an email at: firstname.lastname@example.org